Last reviewed · How we verify
The experimental group received Nivolumab
The experimental group received Nivolumab is a Small molecule drug developed by xiaohua li. It is currently in Phase 2 development. Also known as: Trastuzumab, FLOT.
At a glance
| Generic name | The experimental group received Nivolumab |
|---|---|
| Also known as | Trastuzumab, FLOT |
| Sponsor | xiaohua li |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- 125I Seed Brachytherapy Combined With Immunotherapy for Primary, Recurrent, or Metastatic Malignant Tumors (PHASE2)
- SBRT With Immunotherapy in Early Stage Non-small Cell Lung Cancer: Tolerability and Lung Effects (PHASE1, PHASE2)
- Omega-3 Supplementation and Immunotherapy in Gastric Cancer: A Phase II Trial (PHASE2)
- IT-hu14.18-IL2 With Radiation, Nivolumab and Ipilimumab for Melanoma (PHASE1, PHASE2)
- The Immune Assessment of PD-1 Antibody Therapy in Tumor
- A Multi-center, Two-arm, Phase 2 Clinical Study on the Perioperative Treatment of HER2-positive Resectable Esophagogastric Junctional Adenocarcinoma With Nabulimab Combined With FLOT and Trastuzumab VS FLOT Combined With Trastuzumab (PHASE2)
- Study of Nivolumab for Non-Small Cell Lung Cancer (Stage III) Following Neoadjuvant Chemotherapy Plus Nivolumab and Definitive Concurrent Chemoradiation Therapy (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- The experimental group received Nivolumab CI brief — competitive landscape report
- The experimental group received Nivolumab updates RSS · CI watch RSS
- xiaohua li portfolio CI
Frequently asked questions about The experimental group received Nivolumab
What is The experimental group received Nivolumab?
The experimental group received Nivolumab is a Small molecule drug developed by xiaohua li.
Who makes The experimental group received Nivolumab?
The experimental group received Nivolumab is developed by xiaohua li (see full xiaohua li pipeline at /company/xiaohua-li).
Is The experimental group received Nivolumab also known as anything else?
The experimental group received Nivolumab is also known as Trastuzumab, FLOT.
What development phase is The experimental group received Nivolumab in?
The experimental group received Nivolumab is in Phase 2.
Related
- Manufacturer: xiaohua li — full pipeline
- Also known as: Trastuzumab, FLOT
- Compare: The experimental group received Nivolumab vs similar drugs
- Pricing: The experimental group received Nivolumab cost, discount & access